Literature DB >> 24336325

LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade.

I Tanaka1, H Osada2, M Fujii3, A Fukatsu2, T Hida4, Y Horio4, Y Kondo3, A Sato5, Y Hasegawa6, T Tsujimura5, Y Sekido2.   

Abstract

Malignant mesothelioma (MM) is one of the most aggressive neoplasms usually associated with asbestos exposure and is highly refractory to current therapeutic modalities. MMs show frequent activation of a transcriptional coactivator Yes-associated protein (YAP), which is attributed to the neurofibromatosis type 2 (NF2)-Hippo pathway dysfunction, leading to deregulated cell proliferation and acquisition of a malignant phenotype. However, the whole mechanism of disordered YAP activation in MMs has not yet been well clarified. In the present study, we investigated various components of the NF2-Hippo pathway, and eventually found that MM cells frequently showed downregulation of LIM-domain protein AJUBA, a binding partner of large tumor suppressor type 2 (LATS2), which is one of the last-step kinases of the NF2-Hippo pathway. Although loss of AJUBA expression was independent of the alteration status of other Hippo pathway components, MM cell lines with AJUBA inactivation showed a more dephosphorylated (activated) level of YAP. Immunohistochemical analysis showed frequent downregulation of AJUBA in primary MMs, which was associated with YAP constitutive activation. We found that AJUBA transduction into MM cells significantly suppressed promoter activities of YAP-target genes, and the suppression of YAP activity by AJUBA was remarkably canceled by knockdown of LATS2. In connection with these results, transduction of AJUBA-expressing lentivirus significantly inhibited the proliferation and anchorage-independent growth of the MM cells that harbored ordinary LATS family expression. Taken together, our findings indicate that AJUBA negatively regulates YAP activity through the LATS family, and inactivation of AJUBA is a novel key mechanism in MM cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24336325     DOI: 10.1038/onc.2013.528

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

1.  Scaffold proteins may biphasically affect the levels of mitogen-activated protein kinase signaling and reduce its threshold properties.

Authors:  A Levchenko; J Bruck; P W Sternberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  The LIM protein Ajuba is recruited to cadherin-dependent cell junctions through an association with alpha-catenin.

Authors:  Helene Marie; Stephen J Pratt; Martha Betson; Holly Epple; Josef T Kittler; Laura Meek; Stephen J Moss; Sergey Troyanovsky; David Attwell; Gregory D Longmore; Vania M M Braga
Journal:  J Biol Chem       Date:  2002-11-01       Impact factor: 5.157

3.  YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes.

Authors:  T Mizuno; H Murakami; M Fujii; F Ishiguro; I Tanaka; Y Kondo; S Akatsuka; S Toyokuni; K Yokoi; H Osada; Y Sekido
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

Review 4.  FoxM1: at the crossroads of ageing and cancer.

Authors:  Jamila Laoukili; Marie Stahl; René H Medema
Journal:  Biochim Biophys Acta       Date:  2006-08-30

5.  Hippo pathway regulation by cell morphology and stress fibers.

Authors:  Ken-Ichi Wada; Kazuyoshi Itoga; Teruo Okano; Shigenobu Yonemura; Hiroshi Sasaki
Journal:  Development       Date:  2011-08-10       Impact factor: 6.868

Review 6.  The pathogenesis of mesothelioma.

Authors:  Michele Carbone; Robert A Kratzke; Joseph R Testa
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

7.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Authors:  Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

8.  Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells.

Authors:  Zhiwei Wang; Sanjeev Banerjee; Dejuan Kong; Yiwei Li; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

9.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.

Authors:  Bin Zhao; Xiaomu Wei; Weiquan Li; Ryan S Udan; Qian Yang; Joungmok Kim; Joe Xie; Tsuneo Ikenoue; Jindan Yu; Li Li; Pan Zheng; Keqiang Ye; Arul Chinnaiyan; Georg Halder; Zhi-Chun Lai; Kun-Liang Guan
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

10.  YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation.

Authors:  Toshihiko Yokoyama; Hirotaka Osada; Hideki Murakami; Yoshio Tatematsu; Tetsuo Taniguchi; Yutaka Kondo; Yasushi Yatabe; Yoshinori Hasegawa; Kaoru Shimokata; Yoshitsugu Horio; Toyoaki Hida; Yoshitaka Sekido
Journal:  Carcinogenesis       Date:  2008-08-25       Impact factor: 4.944

View more
  30 in total

1.  TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.

Authors:  Akihiro Matsushita; Tatsuhiro Sato; Satomi Mukai; Teruaki Fujishita; Emi Mishiro-Sato; Maho Okuda; Masahiro Aoki; Yoshinori Hasegawa; Yoshitaka Sekido
Journal:  Oncogene       Date:  2018-11-06       Impact factor: 9.867

2.  Prioritizing predictive biomarkers for gene essentiality in cancer cells with mRNA expression data and DNA copy number profile.

Authors:  Yuanfang Guan; Tingyang Li; Hongjiu Zhang; Fan Zhu; Gilbert S Omenn
Journal:  Bioinformatics       Date:  2018-12-01       Impact factor: 6.937

Review 3.  The mammalian Hippo pathway: regulation and function of YAP1 and TAZ.

Authors:  Manami Kodaka; Yutaka Hata
Journal:  Cell Mol Life Sci       Date:  2014-09-30       Impact factor: 9.261

4.  Role of YAP in lung cancer resistance to cisplatin.

Authors:  Juan Song; Li-Xia Xie; Xin-Yi Zhang; Ping Hu; Mei-Fang Long; Fang Xiong; Juan Huang; Xiao-Qun Ye
Journal:  Oncol Lett       Date:  2018-07-12       Impact factor: 2.967

Review 5.  Disease implications of the Hippo/YAP pathway.

Authors:  Steven W Plouffe; Audrey W Hong; Kun-Liang Guan
Journal:  Trends Mol Med       Date:  2015-02-18       Impact factor: 11.951

Review 6.  Hippo/YAP pathway for targeted therapy.

Authors:  Emanuela Felley-Bosco; Rolf Stahel
Journal:  Transl Lung Cancer Res       Date:  2014-04

7.  Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.

Authors:  Ming Zhang; Ratnakar Singh; Shaohua Peng; Tuhina Mazumdar; Vaishnavi Sambandam; Li Shen; Pan Tong; Lerong Li; Nene N Kalu; Curtis R Pickering; Mitchell Frederick; Jeffrey N Myers; Jing Wang; Faye M Johnson
Journal:  Cancer Lett       Date:  2017-01-23       Impact factor: 8.679

Review 8.  The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

Authors:  Xiao-Lan Liu; Rui Zuo; Wen-Bin Ou
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

9.  Ajuba Phosphorylation by CDK1 Promotes Cell Proliferation and Tumorigenesis.

Authors:  Xingcheng Chen; Seth Stauffer; Yuanhong Chen; Jixin Dong
Journal:  J Biol Chem       Date:  2016-05-18       Impact factor: 5.157

10.  Bayesian inference of negative and positive selection in human cancers.

Authors:  Donate Weghorn; Shamil Sunyaev
Journal:  Nat Genet       Date:  2017-11-06       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.